Medicare Does Not Cover Medical Marijuana, But Some FDA-Approved Cannabinoid Drugs May Qualify
Medicare does not currently cover cannabis purchased from a medical-marijuana dispensary, and there is no announced date when it will begin doing so. The main obstacle is not simply whether individual states legalize cannabis. Medicare coverage generally depends on federal approval, prescription status, and the rules governing Medicare drug benefits.
The Food and Drug Administration’s cannabis overview says it has not approved cannabis itself to treat any disease or condition. It has, however, approved several prescription medicines containing cannabis-derived or cannabis-related compounds, including Epidiolex, Marinol, Syndros, and Cesamet. These are distinct from the flower, edibles, tinctures, and other products sold through state medical-cannabis programs.
That distinction is important for Medicare beneficiaries. Medical marijuana is typically recommended or authorized under state law, but it is not dispensed as an FDA-approved prescription drug. Medicare Part B does not cover the cost of medical-marijuana products, dispensary purchases, state-issued cannabis cards, or related certification fees.
Some FDA-approved cannabinoid medicines may be eligible for coverage through Medicare Part D. Part D plans cover prescription drugs, but each plan maintains its own formulary and may impose requirements such as prior authorization, quantity limits, or restrictions based on the condition being treated. Beneficiaries should check their plan’s drug list rather than assume that every cannabinoid-based prescription will be covered. Medicare’s Part D coverage guide explains how formularies and plan-specific rules work.
Federal legalization of cannabis would not automatically require Medicare to pay for dispensary products. Even if federal law changed, broader Medicare coverage would likely require cannabis products to meet the federal standards that apply to covered prescription drugs, including FDA review and approval or another legally recognized coverage pathway. The CMS Medicare Part D manual describes the program’s definition of a covered Part D drug.
For now, the practical answer is straightforward: Medicare does not cover state-authorized medical marijuana, and no timetable has been established for such coverage. Medicare may cover a specific FDA-approved cannabinoid medication when it is prescribed for an appropriate use and included in a beneficiary’s Part D plan. Patients considering cannabis for a medical condition should discuss FDA-approved alternatives, possible drug interactions, and out-of-pocket costs with their clinician and plan.
